|
1
|
Goodman ZD: Neoplasms of the liver. Mod
Pathol. 20:S49–S60. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Nakanuma Y, Harada K, Ishikawa A, Zen Y
and Sasaki M: Anatomic and molecular pathology of intrahepatic
cholangiocarcinoma. J Hepatobiliary Pancreat Surg. 10:265–281.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Parkin DM, Bray F, Ferlay J and Pisani P:
Global cancer statistics, 2002. CA Cancer J Clin. 55:74–108. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Okuno M, Ebata T, Yokoyama Y, Igami T,
Sugawara G, Mizuno T, Yamaguchi J and Nagino M: Appraisal of
inflammation-based prognostic scores in patients with unresectable
perihilar cholangiocarcinoma. J Hepatobiliary Pancreat Sci.
23:636–642. 2016. View
Article : Google Scholar : PubMed/NCBI
|
|
5
|
Shaib Y and El-Serag HB: The epidemiology
of cholangiocarcinoma. Semin Liver Dis. 24:115–125. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Patel T: Worldwide trends in mortality
from biliary tract malignancies. BMC Cancer. 2:102002. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Sun YF, Xu Y, Yang XR, Guo W, Zhang X, Qiu
SJ, Shi RY, Hu B, Zhou J and Fan J: Circulating stem cell-like
epithelial cell adhesion molecule-positive tumor cells indicate
poor prognosis of hepatocellular carcinoma after curative
resection. Hepatology. 57:1458–1468. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Chiba T, Zheng YW, Kita K, Yokosuka O,
Saisho H, Onodera M, Miyoshi H, Nakano M, Zen Y, Nakanuma Y, et al:
Enhanced self-renewal capability in hepatic stem/progenitor cells
drives cancer initiation. Gastroenterology. 133:937–950. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wu XZ and Yu XH: Bone marrow cells: The
source of hepatocellular carcinoma? Med Hypotheses. 69:36–42. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Borovski T, De Sousa E, Melo F, Vermeulen
L and Medema JP: Cancer stem cell niche: The place to be. Cancer
Res. 71:634–639. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Schiavoni G, Gabriele L and Mattei F: The
tumor microenvironment: A pitch for multiple players. Front Oncol.
3:902013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Biswas SK, Allavena P and Mantovani A:
Tumor-associated macrophages: Functional diversity, clinical
significance, and open questions. Semin Immunopathol. 35:585–600.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Cook J and Hagemann T: Tumour-associated
macrophages and cancer. Curr Opin Pharmacol. 13:595–601. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Sielska M, Przanowski P, Wylot B,
Gabrusiewicz K, Maleszewska M, Kijewska M, Zawadzka M, Kucharska J,
Vinnakota K, Kettenmann H, et al: Distinct roles of CSF family
cytokines in macrophage infiltration and activation in glioma
progression and injury response. J Pathol. 230:310–321. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Staudt ND, Jo M, Hu J, Bristow JM, Pizzo
DP, Gaultier A, VandenBerg SR and Gonias SL: Myeloid cell receptor
LRP1/CD91 regulates monocyte recruitment and angiogenesis in
tumors. Cancer Res. 73:3902–3912. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhang G, Guo L, Yang C, Liu Y, He Y, Du Y,
Wang W and Gao F: A novel role of breast cancer-derived hyaluronan
on inducement of M2-like tumor-associated macrophages formation.
Oncoimmunology. 5:e11721542016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Oishi K, Sakaguchi T, Baba S, Suzuki S and
Konno H: Macrophage density and macrophage colony-stimulating
factor expression predict the postoperative prognosis in patients
with intrahepatic cholangiocarcinoma. Surg Today. 45:715–722. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Mantovani A and Sica A: Macrophages,
innate immunity and cancer: Balance, tolerance, and diversity. Curr
Opin Immunol. 22:231–237. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Liu JY, Yang XJ, Geng XF, Huang CQ, Yu Y
and Li Y: Prognostic significance of tumor-associated macrophages
density in gastric cancer: A systemic review and meta-analysis.
Minerva Med. 107:314–321. 2016.PubMed/NCBI
|
|
20
|
Bao S, Ouyang G, Bai X, Huang Z, Ma C, Liu
M, Shao R, Anderson RM, Rich JN and Wang XF: Periostin potently
promotes metastatic growth of colon cancer by augmenting cell
survival via the Akt/PKB pathway. Cancer Cell. 5:329–339. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Baril P, Gangeswaran R, Mahon PC, Caulee
K, Kocher HM, Harada T, Zhu M, Kalthoff H, Crnogorac-Jurcevic T and
Lemoine NR: Periostin promotes invasiveness and resistance of
pancreatic cancer cells to hypoxia-induced cell death: Role of the
beta4 integrin and the PI3k pathway. Oncogene. 26:2082–2094. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Malanchi I, Santamaria-Martínez A, Susanto
E, Peng H, Lehr HA, Delaloye JF and Huelsken J: Interactions
between cancer stem cells and their niche govern metastatic
colonization. Nature. 481:85–89. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhou W, Ke SQ, Huang Z, Flavahan W, Fang
X, Paul J, Wu L, Sloan AE, McLendon RE, Li X, et al: Periostin
secreted by glioblastoma stem cells recruits M2 tumour-associated
macrophages and promotes malignant growth. Nat Cell Biol.
17:170–182. 2015. View
Article : Google Scholar : PubMed/NCBI
|
|
24
|
Michaylira CZ, Wong GS, Miller CG,
Gutierrez CM, Nakagawa H, Hammond R, Klein-Szanto AJ, Lee JS, Kim
SB, Herlyn M, et al: Periostin, a cell adhesion molecule,
facilitates invasion in the tumor microenvironment and annotates a
novel tumor-invasive signature in esophageal cancer. Cancer Res.
70:5281–5292. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Liu Y, Li F, Gao F, Xing L, Qin P, Liang
X, Zhang J, Qiao X, Lin L, Zhao Q and Du L: Periostin promotes
tumor angiogenesis in pancreatic cancer via Erk/VEGF signaling.
Oncotarget. 7:40148–40159. 2016.PubMed/NCBI
|
|
26
|
Nathan H, Aloia TA, Vauthey JN, Abdalla
EK, Zhu AX, Schulick RD, Choti MA and Pawlik TM: A proposed staging
system for intrahepatic cholangiocarcinoma. Ann Surg Oncol.
16:14–22. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Mantovani A, Sica A, Sozzani S, Allavena
P, Vecchi A and Locati M: The chemokine system in diverse forms of
macrophage activation and polarization. Trends Immunol. 25:677–686.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Popivanova BK, Kostadinova FI, Furuichi K,
Shamekh MM, Kondo T, Wada T, Egashira K and Mukaida N: Blockade of
a chemokine, CCL2, reduces chronic colitis-associated
carcinogenesis in mice. Cancer Res. 69:7884–7892. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Qian BZ, Li J, Zhang H, Kitamura T, Zhang
J, Campion LR, Kaiser EA, Snyder LA and Pollard JW: CCL2 recruits
inflammatory monocytes to facilitate breast-tumour metastasis.
Nature. 475:222–225. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Pyonteck SM, Gadea BB, Wang HW, Gocheva V,
Hunter KE, Tang LH and Joyce JA: Deficiency of the macrophage
growth factor CSF-1 disrupts pancreatic neuroendocrine tumor
development. Oncogene. 31:1459–1467. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Germano G, Frapolli R, Belgiovine C,
Anselmo A, Pesce S, Liguori M, Erba E, Uboldi S, Zucchetti M,
Pasqualini F, et al: Role of macrophage targeting in the antitumor
activity of trabectedin. Cancer Cell. 23:249–262. 2013. View Article : Google Scholar : PubMed/NCBI
|
